BioSpace News Archive

NanoVibronix Inc today announced it has filed three U.S. patent applications with the U.S. Patent & Trademark Office related to its SAW technology and indwelling medical devices to protect targeted new product launches and improvements to existing medical devices.

Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced the company, along with its collaborators, will present new data on Natera’s personalized, tumor-informed molecular residual disease (MRD) test, Signatera, at the American Society of Clinical Oncology’s 2022 Gastrointestinal Cancers Symposium (ASCO GI).

Tivic Health® Systems, Inc., (Nasdaq: TIVC), a commercial-phase healthtech company focused on bioelectronic medicine, today announced initiation of its second clinical study investigating the extension of the company’s bioelectronic platform, offering a potentially new alternative to opioids for post-operative care following sinus surgeries.

The American Cancer Society (ACS) today announced a landmark grant of $9.1 million from the Lisa Dean Moseley Foundation, headquartered in Wilmington, Delaware , to establish the American Cancer Society Lisa Dean Moseley Foundation Cancer Stem Cell Consortium.

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced strong preliminary results for the fourth quarter of 2021, including record growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate).

Vetter, a leading global Contract Development and Manufacturing Organization, has received the manufacturing authorization for its new site in Rankweil, Austria.

Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company, today announced it has completed a license with the University of California San Diego to add a novel gene therapy for the treatment of neurodegenerative diseases.

Adimab, LLC today announced that 12 new partner programs entered clinical development in 2021.

COVID-19 patients with newly diagnosed SARS-CoV-2 infections were treated in these randomized, double-blind, placebo-controlled Phase 2 trials in the US and UK.

Zealand Pharma A/S on pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders.